Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Glaxo Wellcome Changes Its Name to Glaxo SmithKline, Relocates Head Office
January 15, 2001
- Arimidex Approved as 1st Drug Based on Bridging Studies in Japan
January 15, 2001
- Dainippon Starts Full Operation of New PMS Information System
January 15, 2001
- BUSINESS NEWS IN BRIEF -1-
January 15, 2001
- Use of Overseas Data Recommended to Develop Pediatric Drugs
January 15, 2001
- Use New Technology to Meet Existing Needs in Healthcare: Mr Tanimura
January 15, 2001
- BUSINESS NEWS IN BRIEF -2-
January 15, 2001
- CPAC to Become Pharmaceutical Affairs and Food Sanitation Council
January 15, 2001
- Banyu Confirms Efficacy, Safety of Simvastatin in Clinical Trail
January 15, 2001
- CAPC's Executive Committee Recommends Approval of 16 Active Ingredients
January 15, 2001
- medical facilities & nursing care news on brief
January 15, 2001
- REGULATORY NEWS IN BRIEF -2-
January 15, 2001
- Cooperation with Companies Is Essential: RIKEN Researcher
January 15, 2001
- Sales of Takeda's Blopress Skyrocket: Top 100 Products Ranking
January 15, 2001
- Tissue Engineering Chair Donated by BCS at Tokai Univ.
January 15, 2001
- NHI Price System Reform Shelved in Japan: US ITC Report
January 15, 2001
- abbreviation
January 15, 2001
- Growth of Morphine Consumption Slows Down
January 15, 2001
- Welfide: Business Forecasts Affected by Transfer of Business, Shares
January 15, 2001
- REGULATORY NEWS IN BRIEF -1-
January 15, 2001
ページ
Japan’s biotech startups are coming under growing pressure as the Tokyo Stock Exchange (TSE) tightens its rules for companies listed…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…